With European Union (EU) membership providing much of the scientific, regulatory and trade infrastructure for the pharmaceutical industry, the sector has been working together and with government to ensure that Life Sciences is in as strong a position as possible as the UK establishes a new relationship with Europe and the rest of the world.
This work has established industry consensus on the following key issues set of influence the maintenance and growth of a world-leading Life Sciences environment in the UK post-Brexit.
Commercial & Trade
Set up by the Government in July 2016 and supported by the Office for Life Sciences, the UK EU Life Sciences Steering Group is a forum for industry, government, civil servants and key stakeholders to discuss the impact of Brexit on UK Life Sciences.
The group is currently co-chaired by GSK and AstraZeneca. The Life Sciences industry is further represented by the ABPI, the
BioIndustry Association (BIA), the Association of the British Healthcare Industry (ABHI) and the British In Vitro Diagnostics Association (BIVDA).
The key objective of the programme is to determine how to create a world-leading Life Sciences environment in the UK outside of the EU. This includes:
The Steering Group first reported the work of the Programme to the
Ministerial Industry Strategy Group (MISG) in September 2016. At this meeting, an initial report mapping out the issues influencing the sector was discussed, with further meetings building upon this work.
For further information, please contact ABPI's Head of External Affairs, Elliot Dunster.
For media requests, please contact ABPI's Media Relations Manager, Andrew Ross.